Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPX-TI641 in atopic dermatitis and psoriasis
NCT06982352Phase 1Recruiting
- Sponsor
- LAPIX Therapeutics
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of lpx-ti641 in atopic dermatitis (AD) and psoriasis (2 cohorts), sponsored by LAPIX Therapeutics. Primary endpoint: Safety and tolerability after multiple oral doses of LPX-TI641 at 84 days. Started Jun 2025; status: recruiting.
02
Drugs
lpx-ti641
03
Conditions
atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on NCT06982352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982352.